FC engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them
US11359029B2 · kind B2 · utility
0Cited by
33References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 6, 2020 |
| Grant date | Jun 14, 2022 |
| Priority date | — |
| Expiry date | Apr 6, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/75
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.